Suven Pharmaceuticals Q1 FY25 Investor Presentation

Suven Pharmaceuticals Q1 FY25 investor presentation covering operating and financial performance, combined business proforma metrics, and strategic initiatives including the Sapala acquisition and merger update with Cohance Lifesciences. The deck outlines segment-wise strategy and financial performance for the quarter.